INSTRUMENTAL FOR HEART VALVES, Model Measuring Device / Dimensioner - models: 7305UX / 73050OD. Record Record Number 10339190370 의 안전성 경고

Agência Nacional de Vigilância Sanitária (ANVISA)에 따르면, 해당 안전성 경고 는 Brazil 에서 Medtronic Comercial Ltda 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 사례 ID
    1349
  • 날짜
    2014-01-08
  • 사례 국가
  • 사례 출처
    ANVISA
  • 사례 출처 URL
  • 비고 / 경고
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • 데이터 추가 비고
    The company reports that the above-normal transvalvular gradients (> 25 mmHg) of Mosaic Aortic Bioprosthesis occurred at a rate of 0.33 percent (3.3 reports for every 1,000 aortic implants). A subgroup of these valves was explanted within five years of implantation at a general occurrence rate of 0.1 percent (1 explant for every 1,000 aortic implants). Medtronic has determined that the practice of significant oversizing may lead to cases of transvalvular gradients that are higher than expected. Specifically, considerable oversizing, or implanting a valve significantly larger than the native aortic annulus, may result in alteration of the normal movement of the leaflet since the blood flowing through the native ring may not correspond correctly to the size and / or shape of the flow of the Mosaic Aortic Bioprosthesis. In addition, Medtronic concluded that the current Mosaic Aortic Bioprosthesis sizing table (iEOA) and the Shutters / Dimensioners may in some cases contribute to the selection of a larger Mosaic Aortic Bioprosthesis the ideal. #### (10/03/2014): The field action was finalized by the company on 04/08/2014.
  • 원인
    Medtronic received unusual reports of overvalued transvalvular gradients occurring after implantation, not associated with the mosaic mitral ™ bioprosthesis (model 310).
  • 조치
    Medtronic recommends that surgeons remain vigilant in selecting the appropriate size of Mosaic Aortic Bioprostheses. Adoption of the Mosaic Aortic Bioprosthesis sizing chart (iEOA table) and the updated Mosaic Suture / Sizer dimensions will ensure the selection of the ideal aortic valve size. Medtronic is not making any specific recommendations related to the treatment of the patient. Surgeons and cardiologists should continue to follow their implanted patients in accordance with their usual practices and published instructions. The Medtronic Local Representative will contact you regarding the receipt of a set of Mosaic Aortic Shutters / Dimensioners and the new sizing chart as well as for new training.

Manufacturer

  • 제조사 모회사 (2017)
  • 제조사 의견
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    ANVSANVISA